Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...

Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml ...

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

Amgen’s stock has been rising consistently ... Sales of best-selling drugs, Prolia and Xgeva, are expected to decline in 2025 due to biosimilar competition. Let’s understand these factors ...